Arsenal Entered into a Multi-Year Collaboration with Genentech to Identify T-Cell Therapies for Cancer
Shots:
- Arsenal to receive $70M up front & is also eligible to receive research, development & commercial milestones
- The companies will use ArsenalBio’s technology for high-throughput screening, and T-cell engineering to identify the attributes of T-cell-based therapies for cancer patients. Both companies will use their synergistic capabilities to study efficient T cell-based alterations and create new insights into their effects through preclinical analysis
- ArsenalBio's engineering platform develops new synthetic biological programs to improve T cell functions & overcome the complex immunological defense system in solid tumors through the use of technologies i.e., high-throughput CRISPR-based gene editing, synthetic biology & computational biology
Ref: Businesswire| Image: Genentech
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
